|
Douglas Watson has served as Chairman of the Board for OraSure Technologies, Inc., since March 2003, and served on the Board of Directors since May 2002.
Douglas G. Watson is the founder of Pittencrieff Glen Associates, which was established in July 1999. Prior to this, he was President and Chief Executive Officer of Novartis Corporation, the US subsidiary of Novartis A.G. Mr. Watson’s career spanned 33 years with Ciba/Geigy-Geigy/Novartis, during which time he held a variety of positions in the UK, Switzerland and the United States. From 1986, he was President of Ciba US Pharmaceuticals Division until 1996, when he was appointed President & CEO of Ciba-Geigy Corporation. During this ten-year period, Mr. Watson was an active member of the Pharmaceutical Research & Manufacturers Association (PhRMA) board in Washington, DC. Mr. Watson became President & CEO of Novartis Corporation in 1996 when the merger of Ciba-Geigy & Sandoz was approved by the FTC. Mr. Watson elected to take early retirement from Novartis in May 1999.
Mr. Watson also serves as a member of the board of directors for Engelhard Corporation, Dendreon Corporation, Genta Inc., BioMimetic Pharmaceuticals Inc., BZL Biologics Inc., InforMedix Inc., Innovative Drug Delivery Systems Inc., and BioElectronics Inc. He is a member of the board of directors of the American Liver Foundation, is on the President's Advisory Council of Drew University, and Chairman of Freedom House Foundation.
Born near Pittencrieff Glen in the city of Dunfermline, Scotland, Mr. Watson holds an MA degree in pure mathematics from Churchill College, Cambridge University, and is a member of the Chartered Institute of Management Accountants. | 